Case originally accepted in the liver study, but is a cholongio-liver mix. This case will not be removed or change studies, but will be analyzed in the CHOL study and not in the LIHC study.

Patient had a prior papillary transitional cell bladder cancer. No systemic chemotherapy or radiation.

Case submitted is found to be a recurrence after submission

During enrollment, the TSS found the patient had surgery 2 months prior to the TCGA cancer procurement.

TSS confirmed during enrollment that patient had chemoembolization prior to cancer procurement.

History of unacceptable prior treatment related to a prior/other malignancy

TSS confirmed the patient had a prior bladder and prostate cancer with an unknown treatment history which is unacceptable for TCGA cases.

History of acceptable prior treatment related to a prior/other malignancy

Patient had a prior prostate adenocarcinoma treated with locoregional radiation. No systemic chemotherapy

Patient had peroperative neoadjuvant therapy for the TCGA tumor.
Patient had a prior prostate adenocarcinoma treated wtih systemic chemotherapy and locoregional radiation.
Patient had a prior sigmoid colon adenocarcinoma. No systemic chemotherapy or radiation.

Patient had a prior prostate adenocarcinoma treated with systemic chemotherapy.

This is the correct replacement barcode for RNA aliquot UUID: F099F7FB-F07A-4529-83DC-E7023C52A999, which is a replacement aliquot for UUID: baf99a71-0ee9-4f3d-8f35-e350deea64de that was found to have inconclusive identity (RNA only).  Note that while this replacement aliquot is derived from the same portion as the DNA, it was created from a different subportion.

Patient had a prior tumor in the back. No systemic chemotherapy or radiation.

Patient had a prior prostate adenocarcinoma and received regional radiation. No systemic chemotherapy.

Case originally accepted in the liver study, but is not a hepatocellular. This is a Cholangiocarcinoma and will not be removed or change studies, but will be analyzed in the CHOL study and not in the LIHC study.